Amcad Biomed (ROCO:4188) Other Current Payables: NT$8.27 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
47 GF Score
Price NT$10.05
GF Value NT$9.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Amcad Biomed Other Current Payables?

Amcad Biomed ROCO:4188 +1.11% 47 Other Current Payables is NT$8.27 Mil as of Mar. 2026. GuruFocus rates ROCO:4188 with a GF Score™ of 47/100 and a GF Value™ of NT$9.60 (Fairly Valued). The stock has 5 warning signs investors should review.

Amcad Biomed's Other Current Payables for the quarter that ended in Mar. 2026 was NT$8.27 Mil.

Amcad Biomed's quarterly Other Current Payables increased from Sep. 2025 (NT$13.01 Mil) to Dec. 2025 (NT$13.73 Mil) but then declined from Dec. 2025 (NT$13.73 Mil) to Mar. 2026 (NT$8.27 Mil).

Amcad Biomed's annual Other Current Payables increased from Dec. 2023 (NT$14.60 Mil) to Dec. 2024 (NT$15.44 Mil) but then declined from Dec. 2024 (NT$15.44 Mil) to Dec. 2025 (NT$13.73 Mil).

Amcad Biomed Other Current Payables Related Terms

Amcad Biomed Other Current Payables Historical Data

* Premium members only.

The historical data trend for Amcad Biomed's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amcad Biomed Other Current Payables Chart

Amcad Biomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.46 18.09 14.60 15.44 13.73

Amcad Biomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.94 10.86 13.01 13.73 8.27
ROCO:4188
47GF Score
Amcad Biomed Corp ROCO:4188
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amcad Biomed Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$8.27 Mil mean?
Amcad Biomed (ROCO:4188) has a Other Current Payables of NT$8.27 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Amcad Biomed and its competitors.
Is Amcad Biomed's Other Current Payables too high?
Amcad Biomed's current Other Current Payables is NT$8.27 Mil. Overall, Amcad Biomed has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Other Current Payables compare to ABT and SYK?
Amcad Biomed's Other Current Payables of NT$8.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Amcad Biomed and its competitors. Amcad Biomed's current Other Current Payables is NT$8.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.60, compared to a current price of NT$10.05 — trading 4.7% above its estimated fair value. The current Other Current Payables is NT$8.27 Mil. Amcad Biomed's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Other Current Payables is NT$8.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$10.05 is trading 4.7% above its estimated GF Value™ of NT$9.60. GuruFocus considers Amcad Biomed to be Fairly Valued.

Key valuation signals for ROCO:4188:

  • Other Current Payables: NT$8.27 Mil
  • GF Value™: NT$9.60 vs. price of NT$10.05 (4.7% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
47GF Score

Get the complete analysis for ROCO:4188

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.05
Price
NT$9.60
GF Value